Perbandingan Uji Diagnostik Mesothelin Serum dengan CA-125 pada Kanker Ovarium Tipe Epitel



This study was conducted to determine and compare the sensitivity, specificity, PPA and NPV of Mesothelin tumor marker, CA-125, combination of Mesothelin and CA-125 as a tumor marker in patients with epithelial ovarian carcinoma. This is a cross sectional diagnostic test on 30 subjects with malignant dan 30 sunjects with benign ovarian tumors that meet the inclusion and exclusion of research criteria in Department of Obstetrics and Gynecology, Medical Faculty Airlangga University/Dr. Soetomo, Surabaya. Blood sample were taken prior to surgery to examine tumor markers (Mesothelin and CA-125) and ultrasound to evaluate tumor mass, and then histopathology of surgery specimen. Statistical data calculated using SPSS. There is a significant increase of Mesothelin serum level and can be used as a tumor marker (alone or in combination with other methods as a triage tool, consider the use of new cut-off value of 1.75 nmol/L). Sensitivity, specificity, PPV, NPV of CA125 is 70%, 33.3%, 51.2% and 52.6%. Sensitivity, specificity, PPV, NPV of Mesothelin-1 is 50%, 80%, 71.4% and 61.5%. Sensitivity, specificity, PPV, NPV of Mesothelin-2 is 36.7%, 93.4%, 84.6% and 59.6%. Sensitivity, specificit , PPV, NPV combination of CA-125 + Mesothelin-1 is 33.3%, 86.7%, 71.4%, 56.5% and 60%. Sensitivity, specificity, PPV, NPV combination of CA-125 + Mesothelin-2 is 23.3%, 93.3%, 77.8%, and 54.9%. Sensitivity, specificity, PPV, NPV of RMI is 83.3%, 36.7%, 56.8%, and 68.8%. CA-125 (as a single tumor marker) has the highest sensitivity and proved as a simple and effective method for the early detection at general population. Mesothelin-2 (either as a single tumor marker or in combination) is more appropriate for the diagnosis tools (triage, determining the risk of malignant from benign ovarian masses) are better than the current and can be considered to replace CA-125.Keywords: tumor marker, CA-125, Mesothelin, combine tumor marker.ABSTRAKPenelitian ini bertujuan mengetahui dan membandingkan sensitivitas, spesifisitas, PPV, dan NPV antara penanda tumor Mesothelin, CA-125, dan kombinasi Mesothelin dan CA-125 sebagai penanda tumor pada penderita keganasan ovarium tipe epitel. Penelitian ini merupakan uji diagnostik cross sectional terhadap 30 pasien tumor jinak dan 30 pasien tumor ganas tumor ovarium yang memenuhi kriteria inklusi dan kriteria eksklusi di Bagian Obstetri dan Ginekologi FK-Unair/RSU Dr. Soetomo, Surabaya. Dilakukan pengambilan serum darah untuk memeriksa tumor marker (Mesothelin dan CA-125) dan pemeriksaan ultrasonografi sebelum dilakukan tindakan pembedahan. Kemudian dilakukan pemeriksaan patologi anatomi spesimen operasi. Penghitungan data statistik menggunakan SPSS. Hasil penelitian menunjukkan terdapat peningkatan kadar serum Mesothelin yang dapat digunakan sebagai pemeriksaan penanda tumor tunggal atau kombinasi sebagai alat triase dengan mempertimbangkan penggunaan nilai cut-off 1,75 nmol/L. Sensitivitas, spesifisitas, PPV, dan NPV CA125 adalah 70%; 33,3%; 51,2%; dan 52,6%. Sensitivitas, spesifisitas, PPV, dan NPV Mesothelin-1 adalah 50%; 80%; 71,4%; dan 61,5%. Sensitivitas, spesifisitas, PPV, dan NPV Mesothelin-2 adalah 36,7%; 93,4%; 84,6%; dan 59,6%. Sensitivitas, spesifisitas, PPV, dan NPV kombinasi CA-125 + Mesothelin-1 adalah 33,3%; 86,7%; 71,4%; 56,5%; dan 60%. Sensitivitas, spesifisitas, PPV, dan NPV kombinasi CA-125 + Mesothelin-2 adalah 23,3%; 93,3%; 77,8%; dan 54,9%. CA-125 (sebagai penanda tumor tunggal) memiliki sensitivitas tertinggi sehingga merupakan metode sederhana dan efektif untuk deteksi dini pada populasi. Mesothelin-2 (baik sebagai penanda tumor tunggal maupun dalam kombinasi) lebih tepat untuk proses penegakan diagnosis (triase, penentuan risiko massa ovarium ganas dari jinak) yang lebih baik dan dapat menggantikan CA-125.Kata Kunci: penanda tumor, CA-125, Mesothelin, kombinasi CA-125 dan Mesothelin


tumor marke;, CA-125; Mesothelin; combine tumor marker

Full Text: View | Download

DOI: 10.33371/ijoc.v9i2.379

Article Metrics

Abstract View: 1609,
PDF Download: 413


Nakae M, Iwamoto I, Fujino T, Maehata Y, Togami S, Yoshinaga

M, et al. Preoperative plasma osteopontin level as a biomarker

complementary to carbohydrate antigen 125 in predicting

ovarian cancer. The Journal of Obstetrics and Gynaecology

Research 2006;32(3):309-14.

Skates SJ, Jacobs IJ, Knapp RC. Tumor markers in screening

for ovarian cancer. Methods In Molecular Medicine 2001;39:61-

Helzlsouer KJ. Prospective Study of Serum CA-125 Levels as

Markers of Ovarian Cancer. JAMA 1993;269(9):1123.

Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, et

al. Elevation of multiple serum markers in patients with

stage I ovarian cancer. Journal of the National Cancer Institute


Fritsche HA, Bast RC. CA 125 in ovarian cancer: advances

and controversy. Clinical Chemistry 1998;44(7):1379-80.

Kojima T, Oh-eda M, Hattori K, Taniguchi Y, Tamura M, Ochi

N, et al. Molecular cloning and expression of megakaryocyte

potentiating factor cDNA. The Journal of Biological Chemistry


Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation

antigen present on mesothelium, mesotheliomas, and ovarian

cancers. Proc Natl Acad Sci USA 1996;93(1):136-40.

Glass JP, Parasher G, Arias-Pulido H, Donohue R, Prossnitz

ER, Cerilli LA. Mesothelin and GPR30 staining among a

spectrum of pancreatic epithelial neoplasms. International

Journal of Surgical Pathology 2011;19(5):588-96.

Iacobuzio-Donahue CA, Ashfaq R, Maitra A, Adsay NV, Shen-

Ong GL, Berg K, et al. Highly expressed genes in pancreatic

ductal adenocarcinomas: a comprehensive characterization and

comparison of the transcription profiles obtained from three

major technologies. Cancer Research 2003;63(24):8614-22.

Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald

D, et al. Mesothelin expression in human lung cancer. Clinical

cancer research: an official journal of the American Association

for Cancer Research 2007;13(5):1571-5.

Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A,

Yamada S, et al. Clinical significance of serum vascular

endothelial growth factor in malignant pleural mesothelioma.

Journal of thoracic oncology: official publication of the

International Association for the Study of Lung Cancer


Wang K, Bodempudi V, Liu Z, Borrego-Diaz E, Yamoutpoor

F, Meyer A, et al. Inhibition of mesothelin as a novel strategy

for targeting cancer cells. Plos One 2012;7(4):e33214.

Chang MC, Chen CA, Chen PJ, Chiang YC, Chen YL, Mao

TL, et al. Mesothelin enhances invasion of ovarian cancer by

inducing MMP-7 through MAPK/ERK and JNK pathways. The

Biochemical Journal 2012;442(2):293-302.

Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD,

Rosenshein NB, et al. Large-scale serial analysis of gene

expression reveals genes differentially expressed in ovarian

cancer. Cancer Research 2000;60(22):6281-7.

Huang CY, Cheng WF, Lee CN, Su YN, Chien SC, Tzeng YL,

et al. Serum mesothelin in epithelial ovarian carcinoma: a

new screening marker and prognostic factor. Anticancer

Research 2006;26(6C):4721-8.

Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD,

Pingpank J, et al. Detection and quantitation of serum mesothelin,

a tumor marker for patients with mesothelioma and ovarian

cancer. Clinical cancer research: an official journal of the

American Association for Cancer Research 2006;12(2):447-53.

Rein BJ, Gupta S, Dada R, Safi J, Michener C, Agarwal A.

Potential markers for detection and monitoring of ovarian

cancer. J Oncol. 2011;2011:475983.

Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA,

Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein

is a biomarker for ovarian carcinoma. Cancer Research


McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N,

Hellstrom KE, et al. Combining CA 125 and SMR serum

markers for diagnosis and early detection of ovarian carcinoma.

Gynecologic Oncology 2004;95(1):9-15.

Clarke-Pearson DL. Clinical practice. Screening for ovarian

cancer. NEJM 2009;361(2):170-7.

Rauh-Hain JA, Krivak TC, Del Carmen MG, Olawaiye AB.

Ovarian cancer screening and early detection in the general

population. Reviews in Obstetrics & Gynecology 2011;4(1):15-21.

Beyer HL, Geschwindt RD, Glover CL, Tran L, Hellstrom I,

Hellstrom KE, et al. MESOMARK: a potential test for malignant

pleural mesothelioma. Clinical Chemistry 2007;53(4):666-72.

Nagele F, Petru E, Medl M, Kainz C, Graf AH, Sevelda P.

Preoperative CA 125: an independent prognostic factor in

patients with stage I epithelial ovarian cancer. Obstetrics

and Gynecology 1995;86(2):259-64.

Malati T. Tumour markers: An overview. IJCB 2007;22(2):17-31.

Skates SJ, Mai P, Horick NK, Piedmonte M, Drescher CW, Isaacs

C, et al. Large prospective study of ovarian cancer screening

in high-risk women: CA125 cut-point defined by menopausal

status. Cancer Prevention Research 2011;4(9):1401-8.

Collaborative Group on Epidemiological Studies of Ovarian

C, Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer

and oral contraceptives: collaborative reanalysis of data from

epidemiological studies including 23,257 women with ovarian

cancer and 87,303 controls. Lancet 2008;371(9609):303-14.

Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model

in evolution. J Oncol. 2010;2010:932371.

Li J, Dowdy S, Tipton T, Podratz K, Lu WG, Xie X, et al. HE4

as a biomarker for ovarian and endometrial cancer management.

Expert Review of Molecular Diagnostics 2009;9(6):555-66.

Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN. HE4 and

mesothelin: novel biomarkers of ovarian carcinoma in patients

with pelvic masses. APJCP 2010;11(1):111-6.


  • There are currently no refbacks.